<?xml version='1.0' encoding='utf-8'?>
<document id="28320730"><sentence text="Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites."><entity charOffset="74-84" id="DDI-PubMed.28320730.s1.e0" text="Dabrafenib" /></sentence><sentence text="The BRAF inhibitor dabrafenib was recently approved for the treatment of certain BRAF V600 mutation-positive tumors, either alone or in combination therapy with the mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 inhibitor, trametinib"><entity charOffset="19-29" id="DDI-PubMed.28320730.s2.e0" text="dabrafenib" /><entity charOffset="250-260" id="DDI-PubMed.28320730.s2.e1" text="trametinib" /><pair ddi="false" e1="DDI-PubMed.28320730.s2.e0" e2="DDI-PubMed.28320730.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28320730.s2.e0" e2="DDI-PubMed.28320730.s2.e1" /></sentence><sentence text=" This article presents the dabrafenib transporter-mediated drug-drug interaction (DDI) risk assessment, which is currently an important part of drug development, regulatory submission, and drug registration"><entity charOffset="27-37" id="DDI-PubMed.28320730.s3.e0" text="dabrafenib" /></sentence><sentence text=" Dabrafenib and its major circulating metabolites (hydroxy-, carboxy-, and desmethyl-dabrafenib) were investigated as inhibitors of the clinically relevant transporters P-gp, BCRP, OATP1B1, OATP1B3, OCT2, OAT1, and OAT3"><entity charOffset="1-11" id="DDI-PubMed.28320730.s4.e0" text="Dabrafenib" /><entity charOffset="51-59" id="DDI-PubMed.28320730.s4.e1" text="hydroxy-" /><entity charOffset="61-69" id="DDI-PubMed.28320730.s4.e2" text="carboxy-" /><entity charOffset="75-95" id="DDI-PubMed.28320730.s4.e3" text="desmethyl-dabrafenib" /><pair ddi="false" e1="DDI-PubMed.28320730.s4.e0" e2="DDI-PubMed.28320730.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28320730.s4.e0" e2="DDI-PubMed.28320730.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28320730.s4.e0" e2="DDI-PubMed.28320730.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28320730.s4.e0" e2="DDI-PubMed.28320730.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28320730.s4.e1" e2="DDI-PubMed.28320730.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28320730.s4.e1" e2="DDI-PubMed.28320730.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28320730.s4.e1" e2="DDI-PubMed.28320730.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28320730.s4.e2" e2="DDI-PubMed.28320730.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28320730.s4.e2" e2="DDI-PubMed.28320730.s4.e3" /></sentence><sentence text=" The DDI Guidance risk assessment decision criteria for inhibition of BCRP, OATP1B1 and OAT3 were slightly exceeded and therefore a minor DDI effect resulting from inhibition of these transporters remained possible" /><sentence text=" Biliary secretion is the major excretion pathway of dabrafenib-related material (71"><entity charOffset="53-63" id="DDI-PubMed.28320730.s6.e0" text="dabrafenib" /></sentence><sentence text="1% of orally administered radiolabeled dose recovered in feces), whereas urinary excretion was observed as well (22" /><sentence text="7% of the dose)" /><sentence text=" In vitro uptake into human hepatocytes of the dabrafenib metabolites, but not of dabrafenib parent compound, was mediated, at least in part, by hepatic uptake transporters"><entity charOffset="47-57" id="DDI-PubMed.28320730.s9.e0" text="dabrafenib" /><entity charOffset="82-92" id="DDI-PubMed.28320730.s9.e1" text="dabrafenib" /><pair ddi="false" e1="DDI-PubMed.28320730.s9.e0" e2="DDI-PubMed.28320730.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28320730.s9.e0" e2="DDI-PubMed.28320730.s9.e1" /></sentence><sentence text=" The transporters responsible for uptake of the pharmacologically active hydroxy- and desmethyl dabrafenib could not be identified, whereas carboxy-dabrafenib was a substrate of several OATPs"><entity charOffset="73-81" id="DDI-PubMed.28320730.s10.e0" text="hydroxy-" /><entity charOffset="86-106" id="DDI-PubMed.28320730.s10.e1" text="desmethyl dabrafenib" /><pair ddi="false" e1="DDI-PubMed.28320730.s10.e0" e2="DDI-PubMed.28320730.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28320730.s10.e0" e2="DDI-PubMed.28320730.s10.e1" /></sentence><sentence text=" Dabrafenib, hydroxy-, and desmethyl-dabrafenib were substrates of P-gp and BCRP, whereas carboxy-dabrafenib was not"><entity charOffset="1-11" id="DDI-PubMed.28320730.s11.e0" text="Dabrafenib" /><entity charOffset="13-21" id="DDI-PubMed.28320730.s11.e1" text="hydroxy-" /><entity charOffset="27-47" id="DDI-PubMed.28320730.s11.e2" text="desmethyl-dabrafenib" /><pair ddi="false" e1="DDI-PubMed.28320730.s11.e0" e2="DDI-PubMed.28320730.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28320730.s11.e0" e2="DDI-PubMed.28320730.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28320730.s11.e0" e2="DDI-PubMed.28320730.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28320730.s11.e1" e2="DDI-PubMed.28320730.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28320730.s11.e1" e2="DDI-PubMed.28320730.s11.e2" /></sentence><sentence text=" Although a small increase in exposure to carboxy-dabrafenib upon inhibition of OATPs and an increase in exposure to desmethyl-dabrafenib upon inhibition of P-gp or BCRP cannot be excluded, the clinical significance of such increases is likely to be low" /><sentence text="" /></document>